Publication | Open Access

Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer

Phase Ii TrialMedicineGynecologyWeekly PaclitaxelIntermittent ScheduleCancer TreatmentOncologyRadiation OncologyGynecology OncologyMolecular OncologyEndocrine-related CancerOvarian Cancer